Context Therapeutics FY 2025 net loss widens 35% to USD 36 million

Reuters03-24
Context <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY 2025 net loss widens 35% to USD 36 million
  • Context Therapeutics published an annual report on Form 10-K, reporting a net loss of USD 36.1 million and a loss from operations of USD 39.7 million.
  • Research and development expense rose 40% to USD 31.9 million, driven mainly by higher clinical costs for CTIM-76 and higher contract manufacturing and preclinical spending for CT-202, plus higher personnel-related costs.
  • General and administrative expense increased 9% to USD 7.8 million, primarily due to higher salaries and personnel-related costs.
  • Cash and cash equivalents were USD 66.0 million, which management said is expected to fund operations into mid-2027, including Phase 1a dose escalation for CTIM-76 and CT-95 and initiation of patient enrollment for CT-202.
  • Pipeline updates included first patient dosed for CTIM-76 in January 2025 and CT-95 in April 2025, with Phase 1a interim data expected in June 2026 and September 2026, respectively, and a first-in-human CT-202 trial expected to dose the first patient in the third quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-020498), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment